Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: InflaRx is a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, specifically C5a and C5aR. Its lead product, vilobelimab (GOHIBIC), received an Emergency Use Authorization (EUA) from the FDA in April 2023 for critically ill COVID-19 patients and marketing authorization under exceptional circumstances from the European Commission in January 2025 for SARS-CoV-2-induced ARDS. The company is also advancing vilobelimab for Pyoderma Gangrenosum (PG) in a Phase 3 trial and developing an oral C5aR inhibitor, INF904.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (€) | 2023 (€) |
|---|---|---|
| Revenue | 165,789 | 63,089 |
| Cost of Sales | (3,317,039) | (532,262) |
| Gross Profit | (3,151,250) | (469,173) |
| Research & Development Expenses | (35,363,897) | (41,024,131) |
| Sales & Marketing Expenses | (6,756,595) | (4,001,299) |
| General & Administrative Expenses | (13,024,441) | (12,628,756) |
| Net Loss | (46,064,402) | (42,667,529) |
| Cash and Cash Equivalents (End of Period) | 18,375,979 | 12,767,943 |
| Marketable Securities (End of Period) | 36,829,741 | 85,727,461 |
| Accumulated Deficit | (332,192,221) | (286,127,819) |
Note: The company reported a net loss of €46.1 million for 2024. Revenue remains minimal (€0.2 million) derived from hospital sales in the U.S. under the EUA.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by €102,700 (163%) compared to 2023, driven by continued commercialization of GOHIBIC in the U.S. However, sales remain negligible relative to operating costs.
- Cost of Sales Increase: Cost of sales rose significantly by €2.8 million, primarily due to a €2.8 million inventory write-down. This write-down was attributed to unfinished goods quantities exceeding expected sales prior to expiry.
- R&D Expense Reduction: R&D expenses decreased by €5.7 million (14%) to €35.4 million. This was driven by a €8.7 million reduction in third-party costs (manufacturing and clinical trials), partially offset by higher personnel expenses.
- Sales & Marketing Expansion: S&M expenses increased by €2.8 million to €6.8 million, reflecting the first full year of commercial infrastructure build-out in the U.S.
- Government Grants: Other income decreased by €7.9 million to €5.3 million. The decline is due to the conclusion of a specific German federal government grant in June 2023, partially offset by €5.1 million recognized from the German Research Allowance Act (Forschungszulagengesetz).
- Financial Result: Net financial result improved by €4.7 million to €6.9 million, largely due to a €5.5 million increase in foreign exchange gains.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes existing cash, cash equivalents, and marketable securities (totaling approx. €55.2 million as of Dec 31, 2024) will fund operations for at least the next 18 months. The company expects to continue incurring significant losses as it advances clinical trials for vilobelimab (PG) and INF904, and scales commercialization efforts. Additional funding will be required to sustain operations beyond this period.
Key Risks and Contingencies:
- Profitability: The company has a history of significant losses and may never achieve profitability. It relies on future product sales or financing to continue operations.
- Regulatory Status: GOHIBIC's U.S. status is an EUA, which is subject to revocation if the public health emergency declaration ends or safety concerns arise. The European authorization is "under exceptional circumstances" and requires annual reassessment.
- Inventory Obsolescence: Significant risk of inventory write-downs exists due to the limited shelf-life of GOHIBIC and uncertainty regarding future demand for COVID-19 treatments.
- Manufacturing Dependence: The company relies on third-party manufacturers, including a facility in China, creating supply chain and geopolitical risks.
- Capital Needs: Failure to raise additional capital could force the company to delay, reduce, or discontinue development programs.
Important Facts for Investor Verification
- Post-Reporting Financing: In February 2025, the company completed an underwritten public offering raising approximately $30 million (gross) via the sale of 8.25 million ordinary shares and pre-funded warrants.
- European Approval: On January 15, 2025, the European Commission granted marketing authorization for GOHIBIC for SARS-CoV-2-induced ARDS under exceptional circumstances.
- Inventory Write-Downs: Verify the assumptions used for the €2.8 million inventory write-down regarding expected future sales of GOHIBIC prior to expiry.
- Grant Sustainability: Confirm the timeline and eligibility for future reimbursements under the German Research Allowance Act (Forschungszulagengesetz) for expenses incurred from 2025 to 2027.
- Cash Runway: Assess the sufficiency of the €55.2 million in liquid assets against the projected burn rate, considering the upcoming Phase 3 interim analysis for PG (expected Q2 2025) and commercialization costs.